Rigel reports prelim Q4 total revenue $57.6M, guides FY2025 rev $200-210M

RIGEL PHARMACEUTICALS INC

Q4 2024 total revenue $57.6M vs $35.8M Q4 2023; net product sales $46.5M.
TAVALISSE net sales $31.0M, REZLIDHIA $7.4M, GAVRETO $8.1M (launched June 2024).
Full-year 2024 total revenue $179.3M; cash & equivalents $77.3M at year-end.
2025 guidance: total revenue $200-210M; expects positive net income for the year.
R289 granted Orphan Drug designation by FDA for MDS; Phase 1b enrollment ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.